Sequist LV - Search Results

1

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN. Nangia V, et al. Among authors: sequist lv. Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25. Cancer Discov. 2018. PMID: 30254092 Free PMC article.

2

Treatment of advanced non-small cell lung cancer in the elderly.

Sequist LV, Fidias P. Sequist LV, et al. Semin Respir Crit Care Med. 2005 Jun;26(3):289-97. doi: 10.1055/s-2005-871987. Semin Respir Crit Care Med. 2005. PMID: 16052430 Review.

3

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.

Sequist LV, Haber DA, Lynch TJ. Sequist LV, et al. Clin Cancer Res. 2005 Aug 15;11(16):5668-70. doi: 10.1158/1078-0432.CCR-05-1055. Clin Cancer Res. 2005. PMID: 16115901 No abstract available.

4

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Sequist LV, Bell DW, Lynch TJ, Haber DA. Sequist LV, et al. J Clin Oncol. 2007 Feb 10;25(5):587-95. doi: 10.1200/JCO.2006.07.3585. J Clin Oncol. 2007. PMID: 17290067 Review.

5

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Sequist LV. Sequist LV. Oncologist. 2007 Mar;12(3):325-30. doi: 10.1634/theoncologist.12-3-325. Oncologist. 2007. PMID: 17405897 Free article. Review.

6

Update on epidermal growth factor receptor inhibitor development in lung cancer.

Sequist LV, Dziadziuszko R. Sequist LV, et al. J Thorac Oncol. 2006 Sep;1(7):740-3. J Thorac Oncol. 2006. PMID: 17409951 Free article.

7

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.

Sequist LV, Lynch TJ. Sequist LV, et al. Annu Rev Med. 2008;59:429-42. doi: 10.1146/annurev.med.59.090506.202405. Annu Rev Med. 2008. PMID: 17716025 Review.

8

Non-small cell lung cancer in octogenarians: treatment practices and preferences.

Oxnard GR, Fidias P, Muzikansky A, Sequist LV. Oxnard GR, et al. Among authors: sequist lv. J Thorac Oncol. 2007 Nov;2(11):1029-35. doi: 10.1097/JTO.0b013e318158d4a2. J Thorac Oncol. 2007. PMID: 17975495 Free article.

9

Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.

Lynch TJ Jr, Blumenschein GR Jr, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Lynch TJ Jr, et al. Among authors: sequist lv. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12. doi: 10.1097/JTO.0b013e318174e9d3. J Thorac Oncol. 2008. PMID: 18520291 Free article.

10

First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.

Sequist LV. Sequist LV. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S143-5. doi: 10.1097/JTO.0b013e318174e981. J Thorac Oncol. 2008. PMID: 18520299 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

283 results

Search Page